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Summary
 
Infection of target cells by HIV-1 requires initial binding interactions between the viral enve-
lope glycoprotein gp120, the cell surface protein CD4, and one of the members of the seven-
transmembrane G protein–coupled chemokine receptor family. Most primary isolates (R5
strains) use chemokine receptor CCR5, but some primary syncytium-inducing, as well as T
cell line–adapted, strains (X4 strains) use the CXCR4 receptor. Signaling from both CCR5
and CXCR4 is mediated by pertussis toxin (PTX)-sensitive G
 
i
 
 proteins and is not required for
HIV-1 entry. Here, we show that the PTX holotoxin as well as its binding subunit, B-oligo-
mer, which lacks G
 
i
 
-inhibitory activity, blocked entry of R5 but not X4 strains into primary T
lymphocytes. Interestingly, B-oligomer inhibited virus production by peripheral blood mono-
nuclear cell cultures infected with either R5 or X4 strains, indicating that it can affect HIV-1
replication at both entry and post-entry levels. T cells treated with B-oligomer did not initiate
signal transduction in response to macrophage inflammatory protein (MIP)-1
 
b
 
 or RANTES
(regulated upon activation, normal T cell expressed and secreted); however, cell surface expres-
sion of CCR5 and binding of MIP-1
 
b
 
 or HIV-1 to such cells were not impaired. The inhibi-
tory effect of B-oligomer on signaling from CCR5 and on entry of R5 HIV-1 strains was re-
versed by protein kinase C (PKC) inhibitors, indicating that B-oligomer activity is mediated by
signaling events that involve PKC. B-oligomer also blocked cocapping of CCR5 and CD4 in-
duced by R5 HIV-1 in primary T cells, but did not affect cocapping of CXCR4 and CD4 after
inoculation of the cultures with X4 HIV-1. These results suggest that the B-oligomer of PTX
cross-deactivates CCR5 to impair its function as a coreceptor for HIV-1.
Key words: CCR5 • signal transduction • G
 
i
 
 protein • receptor capping • receptor 
desensitization
 
I
 
nfection of the target cells by HIV-1 is initiated by inter-
action between the viral envelope protein, gp120, and a
specific set of cell surface receptors. In addition to CD4,
which has long been recognized as an essential component
of the receptor for HIV and SIV (1), several chemokine re-
ceptors have been shown recently to function as corecep-
tors (for review see reference 2). Despite a wide variety of
chemokine receptors, all primary M-tropic strains of HIV-1
described to date have been shown to be capable of using
CC chemokine receptor (CCR)5
 
1
 
 (3–8), a receptor for CC
chemokines macrophage inflammatory protein (MIP)-1
 
a
 
,
MIP-1
 
b
 
, and RANTES (regulated upon activation, normal
T cell expressed and secreted). The major coreceptor for T
cell line–adapted HIV-1 strains is CXCR4 (9), a receptor
for a CXC chemokine, stroma-derived factor (SDF)-1
 
a
 
.
CXCR4 can be used also by syncytium–inducing primary
strains that appear at the late stages of AIDS progression (8,
10–12).
Chemokine receptors belong to a group of seven-trans-
membrane receptors that transduce signals via coupling to
G proteins. Both CCR5 and CXCR4 are believed to be
coupled to G
 
i
 
-like proteins, based on their sensitivity to
pertussis toxin (PTX) (13). Binding of a ligand (a chemo-
kine or HIV-1) to these receptors induces a characteristic
Ca
 
2
 
1
 
 flux and tyrosine phosphorylation (13–15), which can
be blocked by pretreatment of the cells with PTX. How-
ever, this signaling appears to be unimportant for the func-
 
1
 
Abbreviations used in this paper:
 
 CCR, CC chemokine receptor; CXCR,
CXC chemokine receptor; MCP, monocyte chemoattractant protein;
MIP, macrophage inflammatory protein; PKC, protein kinase C; PTX,
pertussis toxin; RANTES, regulated upon activation, normal T cell ex-
pressed and secreted; SDF, stroma-derived factor. 
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tion of chemokine receptors as coreceptors for HIV-1, at
least in immortalized cells overexpressing chemokine re-
ceptors (16–20). Indeed, transfection into CCR5-negative
cells of mutant receptors unable to couple to G proteins
and transduce signals makes such cells fully susceptible to
infection with R5 HIV-1 strains. In contrast, HIV-1 infec-
tion of primary CD4
 
1
 
 T cells appears to require actin-
mediated rearrangement of receptors (21), implying a sig-
nal-mediated process.
PTX is the major virulence factor of 
 
Bordetella pertussis
 
,
the causative agent of whooping cough. PTX is a 105-kD
noncovalently linked heterohexameric protein, which can
be functionally divided into an enzymatically active A-pro-
tomer and a B (binding)-oligomer. The A-protomer con-
sists of a single peptide subunit (S1) with ADP-ribosyltrans-
ferase activity, which specifically ribosylates and inactivates
the 
 
a
 
-subunit of G
 
i
 
 proteins, thus leading to uncoupling of
corresponding signal transduction events (22, 23). The
B-oligomer is a pentameric protein complex composed of
two dimers (S2-S4 and S3-S4) joined together by the S5
subunit, and is responsible for target cell binding (for re-
view see reference 24). The preferential binding sites for
PTX are carbohydrate moieties (25), but cell surface mole-
cules bearing these carbohydrate determinants have not yet
been unequivocally identified. In lymphocytes, a 70-kD
protein (p70) exhibiting features of the PTX receptor has
been described (26–28); however, p70 may be only one
part of a complex receptor, as PTX was shown to interact
also with smaller cell surface proteins of 43 and 50 kD (27,
29). Treatment of T lymphocytes with PTX or purified
B-oligomer induced a signaling response typical of ligand–
receptor interaction, characterized by an increase of dia-
cylglycerol levels and protein kinase C (PKC) activity, and
by Ca
 
2
 
1
 
 flux (30–32). Thus, it is not surprising that a num-
ber of biological effects of PTX are mediated by its B-oli-
gomer, independently of G
 
i
 
 protein inactivation (for re-
view see reference 24).
One such activity of PTX and B-oligomer is described
in this report. We demonstrate that treatment of primary T
cells with PTX or B-oligomer induces a specific desensiti-
zation of CCR5. As a result, such cells do not respond to
stimulation with a CCR5 ligand, MIP-1
 
b
 
, and do not sup-
port entry of CCR5-dependent HIV-1 strains.
 
Materials and Methods
 
Reagents.
 
PTX was purchased from Sigma Chemical Co. and
B-oligomer was from Calbiochem. The purity of B-oligomer
was verified by gel electrophoresis analysis, which revealed
complete lack of contamination with A-protomer. MIP-1
 
b
 
,
RANTES, and SDF-1
 
a
 
 were from PeproTech, and Fura-2/AM,
Ro-31-8220, and Gö 6979 were from Calbiochem.
 
Primary Lymphocyte Cultures.
 
T cell–enriched, monocyte-depleted
cultures were established from PBMCs from HIV-1–negative do-
nors by Ficoll-Hypaque gradient centrifugation and two rounds
of adherence to plastic. Nonadherent cells were collected by cen-
trifugation, resuspended in RPMI 1640 supplemented with 10%
heat-inactivated FCS, and stimulated with phytohemagglutinin
 
(5 
 
m
 
g/ml) for 3 d. Cells were then washed and cultured for an-
other 7 d in medium supplemented with 20 U/ml of recombi-
nant IL-2. By that time, 
 
z
 
84% of the cells were CD3
 
1
 
, 
 
z
 
40%
were CD4
 
1
 
, 
 
z
 
30% were CCR5
 
1
 
, 
 
z
 
95% were CXCR4
 
1
 
,
 
z
 
10% were CCR5
 
1
 
CD4
 
1
 
, and 
 
z
 
35% were CXCR4
 
1
 
CD4
 
1
 
, as
determined by flow cytometry.
 
Infection with HIV-1.
 
Five HIV-1 strains were used in this
study: three R5 viruses (92US660, 92US657, and ADA) and two
X4 strains (92UG21, a primary isolate, and LAI, a T cell line–
adapted virus). Before infection, viral stocks were treated with
200 U/ml of RNase-free DNase for 1 h at room temperature to
eliminate DNA contamination. Viral inoculae were adjusted ac-
cording to reverse transcriptase activity to 6 
 
3
 
 10
 
4
 
 cpm per 10
 
6
 
cells. After a 2-h adsorption, cells were washed and cultured in
IL-2–supplemented medium.
 
Immunofluorescent Microscopy.
 
Cells were treated with B-oli-
gomer (1 nM) for 10 min and then inoculated with heat-inacti-
vated HIV-1 (2 
 
3
 
 10
 
6
 
 cpm/ml of reverse transcriptase activity) or
with 5 
 
m
 
g/ml of recombinant gp120
 
JR-FL
 
 (Progenics Pharmaceu-
ticals) or gp120
 
LAI
 
 (Intracel). After 60 min at 37
 
8
 
C, cells were
washed and fixed in 4% buffered formaldehyde. After washing,
cells were incubated for 20 min in 1% FCS/PBS at room temper-
ature, and 2 
 
3
 
 10
 
5
 
 cells were incubated for 30 min at room tem-
perature in 0.1 ml of 1% FCS/PBS with anti-CCR5 or anti-
CXCR4 mAb (2D7 and 12G5, respectively, obtained from
PharMingen; both antibodies neutralize HIV-1 infection), fol-
lowed by a 30-min incubation with a secondary rhodamine-
labeled anti–mouse IgG. After washing, cells were incubated
with FITC-labeled anti-CD4 mAb (13B8.2, Immunotech; this
antibody does not compete with gp120 for CD4 binding), then
washed, spotted on slides, dried, and analyzed on an immunoflu-
orescent imaging system using a dedicated software (MetaMorph;
Universal Imaging Corporation).
 
Binding Studies.
 
For each binding reaction, 10
 
6
 
 cells resus-
pended in binding buffer (50 mM Hepes, pH 7.4, 1 mM CaCl
 
2
 
,
5 mM MgCl
 
2
 
, and 0.5% BSA) were mixed with B-oligomer (1 nM),
incubated for 10 min at 37
 
8
 
C, and then transferred to ice. 550
pM of 
 
125
 
I-labeled MIP-1
 
b
 
 (specific activity 2,200 Ci/mmol) was
added to cells in the presence or absence of a 1,000-fold molar
excess of unlabeled MIP-1
 
b
 
, or 0.5 
 
m
 
g/ml of gp120, and reac-
tions were incubated at 4
 
8
 
C for 4 h on a horizontal shaker. After
washing with binding buffer containing 0.5 M NaCl, cell-bound
radioactivity was counted in a gamma-counter.
 
Calcium Mobilization Assay.
 
The assay was performed as pre-
viously described (33). In brief, 0.6 ml of Fura-2–loaded cells (5 
 
3
 
10
 
6
 
 cells/ml) was transferred to an acrylic cuvette and stimulated
with B-oligomer (500 ng/sample), SDF-1
 
a
 
 (100 ng/sample), or
MIP-1
 
b
 
 (500 ng/sample). Fluorescence emission at 340 and 380 nm
was measured on a Perkin-Elmer Luminescence Spectrometer
LS50B.
 
Results and Discussion
 
Several previously published reports (16–20) demon-
strated that activity of chemokine receptors as coreceptors
for HIV-1 does not involve signaling via coupled G
 
i
 
 pro-
teins. A somewhat conflicting result has been reported re-
cently (21), demonstrating that entry of X4 HIV-1 strains
into primary T cells correlated with actin-dependent co-
capping of CD4 and CXCR4 receptors, thus implicating
signaling in the process of HIV-1 entry. To better define
the role of signaling from chemokine receptors in HIV-1 
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entry into primary T cells, we used PTX to specifically in-
activate G
 
i
 
-like proteins that transduce signals from both
CCR5 and CXCR4 (13), and measured HIV-1 entry by
PCR, using primers LTR R/U5 specific for early products
of reverse transcription (34). The fragment of HIV-1
cDNA amplified by these primers is produced either within
the virion or very early after virus–cell fusion, and thus re-
flects the efficiency of virus entry. Surprisingly, PTX inhib-
ited entry of R5 HIV-1 strains 92US660 (Fig. 1 A) and
ADA (not shown), but not of X4 strains LAI (Fig. 1 A) and
92UG21 (not shown). PTX is a complex protein com-
posed of an active (A) and a binding (B) subunit, and cer-
tain T cell activities have been shown to be initiated by the
B-oligomer of PTX independently of inactivation of G
 
i
 
-
like proteins by the A-protomer (35). We therefore tested
whether activity of B-oligomer could account for the ob-
served inhibitory effect of PTX on entry of R5 HIV-1.
Similar to results observed with PTX, B-oligomer inhib-
ited entry of R5 HIV-1 strains in a dose-dependent fash-
ion, but not of X4 HIV-1 strains (Fig. 1 B). Analysis of the
B-oligomer preparation by SDS-PAGE confirmed the lack
of A-protomer (not shown), and G
 
i
 
-mediated signaling was
not impaired in B-oligomer–treated cells (see Fig. 4, right).
We thus conclude that PTX blocks entry of R5 HIV-1
strains by a mechanism that is independent of G
 
i
 
 protein
inhibition. Interestingly, no inhibitory activity of PTX or
B-oligomer was observed on entry of R5 HIV-1 into PM1
cells (not shown), consistent with recently reported results
(36). This result underscores the differences between the
primary cells and T cell lines.
To analyze the effect of B-oligomer on HIV-1 replica-
tion in long-term cultures, we measured virus production
after in vitro
 
 
 
infection of primary PBMCs from HIV-
seronegative donor with R5 or X4 HIV-1 strains. As pre-
dicted from the entry studies (Fig. 1), B-oligomer at 1 nM
 
concentration inhibited replication of a primary R5 strain,
92US660 (Fig. 2 A). Unexpectedly, a similar level of inhi-
bition was also observed with primary (92UG21; Fig. 2 B)
and cell line–adapted (LAI; Fig. 2 C) X4 strains, entry of
which was not affected by B-oligomer (Fig. 1). This result
is consistent with recently reported (37) inhibitory effect of
PTX on replication in PBMCs of another X4 strain, RF,
and indicates that, in addition to its effect on HIV-1 entry
via the CCR5 receptor, B-oligomer exerts its anti-HIV ac-
tivity via another, as yet unidentified, mechanism that
works at the post-entry step of viral replication and does
not depend on the identity of chemokine receptor used by
the virus. Interestingly, this post-entry inhibitory effect of
B-oligomer depended on the multiplicity of infection and
was overcome when high virus inoculum was used (data
not shown). Similar to results of entry studies, replication
of neither R5 (92US660) nor X4 (LAI) strains was inhib-
ited in PM1 cells (Fig. 2, A and C, insets). To further in-
vestigate the anti-HIV activity of B-oligomer, we analyzed
its effect on replication of uncloned primary HIV-1 in co-
cultures of uninfected donor PBMCs with activated PBMCs
from HIV-1–infected patients. The number of infected
cells in the PBMCs from such patients is usually low (38),
so the measured virus output in cocultures is primarily a re-
sult of virus spread to new targets. A dose-dependent inhi-
bition of virus replication by B-oligomer was observed
(Fig. 2 D). This effect was reproduced with PBMCs from
three different patients (not shown); in all cases 1 nM of
B-oligomer completely inhibited virus replication. To
demonstrate that the inhibitory effect of B-oligomer was
not due to its cytotoxic activity, we measured uptake of
[
 
3
 
H]thymidine and the change in cell numbers in long-
term cultures. As shown in Fig. 2 E, no significant differ-
ence in thymidine uptake between B-oligomer–treated and
untreated cultures was observed during the whole course of
Figure 1. The effect of PTX and B-oligomer on HIV-1 entry. (A) Monocyte-depleted PBMC cultures were treated with PTX (1 nM) or left un-
treated (control), and inoculated with R5 HIV-192US660 or X4 HIV-1LAI. Viral entry was analyzed by PCR using primers LTR R/U5 specific for the
early reverse transcription product, as described previously (34). Results were quantified on a Direct Imager (Packard Instrument Company) and are pre-
sented as a percentage of counts in treated versus control samples. The error bars show the deviation from the mean for triplicate samples. Similar results
were obtained in two independent experiments with cells from different donors. (B) Cells were treated with the indicated concentrations of B-oligomer
or an anti-CD4 mAb Leu3A for 10 min or were left untreated and inoculated with HIV-192US660 (left) or HIV-1LAI (middle). Viral entry was analyzed as
in A. In parallel, each sample was amplified with a-tubulin–specific primers to control for the total amount of DNA. Results were quantified on a Pack-
ard Direct Imager and are presented on bar graphs as mean counts for each set of duplicate samples, expressed as counts per minute (cpm). The error bars
show the deviation from the mean for each duplicate. Uninfected cells (Neg.) served as negative control. Dilutions of 8E5/LAI cells containing one
HIV-1 genome per cell (45) were used as PCR standards (right). 
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the experiment. In fact, treated cultures demonstrated
higher proliferation rate (Fig. 2 E, inset), consistent with
the well-known mitogenic effect of B-oligomer (24).
Therefore, B-oligomer inhibits replication of a wide vari-
ety of primary and cell line–adapted isolates. This result
may explain a recently reported inhibitory effect of PTX
on replication of SIV
 
mac251
 
 (which uses the CCR5 recep-
tor) in vivo (39). The inhibitory effect of B-oligomer is ex-
erted at both the entry (for R5 strains) and post-entry
(probably for both R5 and X4 viruses) steps of HIV-1 in-
fection. In this work, we concentrated on the mechanisms
of B-oligomer–mediated inactivation of CCR5.
A possible mechanism by which B-oligomer could spe-
cifically inhibit entry of R5 but not X4 HIV-1 strains is by
interfering with binding of the virus, either directly (by
blocking the HIV-1 binding site on CCR5) or indirectly
(by changing conformation of CCR5). To test this possi-
bility, we performed binding studies with 
 
125
 
I-labeled MIP-
1
 
b
 
 and gp120. Results in Fig. 3 A demonstrate that binding
of MIP-1
 
b
 
 to PBMCs was competed by recombinant
Figure 2. B-oligomer inhibits HIV-1 replication. For in vitro
infection, monocyte-depleted PBMCs from HIV seronegative
donor or PM1 T cell line (insets) were pretreated for 1 h with 1
nM of B-oligomer and infected with primary R5 (92US660,
panel A) or X4 (92UG21, panel B) strains, or T cell line–adapted
X4 virus LAI (panel C). Subsequent culturing was in the pres-
ence of 1 nM of B-oligomer. For direct analysis of clinical iso-
lates, monocyte-depleted PBMCs from HIV-1–infected patients
were activated for three days with PHA and then cocultured
with similarly activated PBMCs from uninfected donors in the
presence of the indicated concentrations of B-oligomer (panel
D). Virus replication was assayed in triplicate cultures, and error
bars show the standard deviations of the mean. A representative
experiment out of three performed with cells from different do-
nors or patients is shown. The uptake of [3H]thymidine was
measured in triplicate long-term cultures of uninfected PBMCs
treated with indicated concentrations of B-oligomer (panel E).
Error bars show standard deviation of the mean. In parallel we
measured the number of cells in each culture (Fig. 2 E, inset). 
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gp120 of an R5 strain, HIV-1
 
JR-FL
 
, but not by gp120 of an
X4 strain, HIV-1
 
LAI
 
. Although treatment of the cells with
B-oligomer increased 
 
125
 
I-labeled MIP-1
 
b
 
 binding three-
fold, binding of this ligand was still effectively competed by
gp120
 
JR-FL
 
 (Fig. 3 A). To exclude the possibility that B-oli-
gomer nonspecifically affected binding of CCR5 ligands,
for instance by acting as a bridge between the ligand and
the cell, analysis was also performed using cells treated for
10 min either with B-oligomer at 4
 
8
 
C (to block signaling
from B-oligomer receptor), or with BSA at 37
 
8
 
C (to
mimic the protein concentration in the experimental sam-
ples). Both treatments had no effect on 
 
125
 
I-labeled MIP-
1
 
b
 
 binding, compared with untreated sample (Fig. 3 B).
Therefore, we conclude that the inhibitory activity of the
B-oligomer on HIV-1 entry is a signal-mediated process
that does not involve blocking of HIV-1 binding to its re-
ceptors. This result also suggests that binding of gp120 to
CD4 and CCR5 is not sufficient to induce fusion of the vi-
ral and cellular membranes.
A logical conclusion from the results presented above is
that a post-binding step of virus entry was inhibited in
B-oligomer–treated cells, and that this effect could be me-
diated by B-oligomer–induced alteration of an intracellular
portion of the CCR5 molecule. As this part of the receptor
is involved in interactions with coupled G proteins, we
measured Ca
 
2
 
1
 
 mobilization in response to natural ligands
of CCR5 and CXCR4, MIP-1
 
b
 
 or RANTES, and SDF-1
 
a
 
,
respectively, after pretreatment of the cells with B-oligo-
mer. Treatment of the cells with B-oligomer blocked Ca
 
2
 
1
 
flux initiated by MIP-1
 
b
 
 (Fig. 4 A) and RANTES (not
shown), but not by SDF-1
 
a
 
 (Fig. 4 B). Although pretreat-
ment of the cells with MIP-1
 
b
 
 desensitized response to
B-oligomer (Fig. 4 C), pretreatment with SDF-1
 
a
 
 induced
only partial desensitization (Fig. 4 D). Of note, B-oligomer
at the suboptimal concentration used in these experiments
(2 nM) did not desensitize its own receptor (not shown).
The use of higher concentrations of B-oligomer for desen-
sitization studies was confounded by a very slow return of
the Ca21 response to the baseline (.30 min), thus preclud-
ing analysis by Fura-2–based technique due to leaking of
the dye from the cells. The pattern of Ca21 response to se-
quential treatment of cells with B-oligomer and MIP-1b is
best described by the phenomenon of heterologous desen-
sitization. Potentially, this desensitization is attributable to
signaling from a B-oligomer receptor, similar to the heter-
ologous desensitization of CXCR1 and CXCR2 chemo-
kine receptors by signaling from opiate receptors (40).
Figure 3. B-oligomer does not block ligand bind-
ing to CCR5. Analysis of 125I-labeled MIP-1b bind-
ing to untreated or B-oligomer–treated PBMCs was
performed as described in Materials and Methods.
Binding was also measured in the presence of either a
1,000-fold molar excess of unlabeled (cold) MIP-1b,
or 0.5 mg/ml of gp120 of an R5 (JR-FL) or X4
(LAI) HIV-1 strain (A). To control for nonspecific
effects of the B-oligomer, binding was analyzed also
using cells treated either with B-oligomer (1 nM) at
48C, or with 75 ng/ml of BSA at 378C (B). Results
are presented as means of duplicate samples, and the
error bars show the deviation from the mean for each
duplicate.
Figure 4. Analysis of cross-desensitization of chemokine and PTX re-
ceptors. Fura-2–loaded PBMCs were stimulated with 0.83 mg/ml of
B-oligomer (B-ol.) (A and B), 1.66 mg/ml of MIP-1b (C), or 0.1 mg/ml
of SDF-1a (D) at the time indicated by the left arrow. At the time indi-
cated by the right arrow (3–5 min later), cells were rechallenged with
B-oligomer (C and D), MIP-1b (A), or SDF-1a (B) at the same concentra-
tion as in the first challenge. Results of one representative experiment out
of three performed with cells from different donors are presented as the
ratio of fluorescence emissions at 340 and 380 nm (F340/F380) over time.602 HIV-1 Inhibition by the Binding Subunit of Pertussis Toxin
Although we can not formally rule out the possibility that
B-oligomer binds to CCR5, several considerations make this
scenario unlikely. First, B-oligomer did not compete with
MIP-1b or gp120 for binding to CCR5 (Fig. 3). Second,
B-oligomer did not induce downregulation of CCR5, as
evidenced by flow cytometric analysis (not shown). Third,
B-oligomer did not induce Ca21 flux (not shown) and did
not affect HIV-1 replication (Fig. 2) in PM1 cells, support-
Figure 5. The effect of B-oligomer on CCR5 is reversed by PKC inhibitor. (A) Ro-31-8220 reverses the inhibitory effect of B-oligomer on entry of
R5 strains. PBMC cultures were either left untreated (control) or treated with B-oligomer (1 nM for 10 min) with or without Ro-31-8220 (pretreat-
ment for 20 min with 10 nM of the inhibitor). Entry of R5 (92US660) or X4 (LAI) strains of HIV-1 was measured as described in the legend to Fig. 1.
Results are presented as mean of two independent experiments with cells from the same donor. The error bars show the deviation from the mean for du-
plicate samples. Similar results were obtained with cells from a different donor. (B) Ro-31-8220 reverses the inhibitory effect of B-oligomer on signaling
from CCR5. PBMC cultures were either treated with B-oligomer (1 nM) alone or in combination with Ro-31-8220 (10 nM) (panels a and c) or left un-
treated (control) or treated with Ro-31-8220 (100 nM) alone (panels b and d) and stimulated with 500 ng/ml of RANTES (panels a and b) or 100 ng/
ml of SDF-1a (panels c and d) at the time indicated by the arrow. Ca21 flux was measured as described in the legend to Fig. 4.
Figure 6. Analysis of receptor capping by immunofluorescent microscopy. PBMCs were treated with 1 nM of B-oligomer for 10 min or left untreated, and
receptor capping was analyzed by a dual-color immunofluorescent microscopy after inoculation with R5 HIV-192US660 (A) or X4 HIV-1LAI (B) viruses. CD4
was revealed with FITC-conjugated anti-CD4 mAb (thus producing green fluorescence), while chemokine receptors were stained with unlabeled pri-
mary and rhodamine-labeled secondary antibody (red fluorescence). Colocalization of receptors resulted in overlapping of red and green fluorescence,
thus producing yellow color. Approximately 50 and 30% of CD4/CCR5 and CD4/CXCR4 double-positive cells, respectively, exhibited capping.603 Alfano et al.
ing the notion that B-oligomer signals through its own re-
ceptor and this signaling is required for its anti-HIV activity.
Treatment of T lymphocytes with PTX or B-oligomer
has been reported to rapidly increase PKC activity (30). To
determine whether PKC was involved in the observed ef-
fects of B-oligomer on CCR5 function, we used two se-
lective PKC inhibitors, Ro-31-8220 and Gö 6979. As
shown in Fig. 5, Ro-31-8220 reversed the inhibitory effect
of B-oligomer on entry of R5 HIV-1 (Fig. 5 A, panel a)
and on Ca21 flux induced by RANTES, another ligand for
CCR5 (Fig. 5 B, panel a). On its own, Ro-31-8220 did
not significantly alter either of those activities of CCR5
(Fig. 5, A and B, panel b). It also did not act upon entry of
X4 HIV-1 (Fig. 5 A, panel b) or signaling by SDF-1a (Fig.
5 B, panels c and d), which are mediated by CXCR4 and
are not affected by B-oligomer. A similar result was ob-
served with a different PKC inhibitor, Gö 6979 (not
shown). Taken together, these results indicate that PKC
is involved in signal transduction from B-oligomer (and
PTX) receptor to CCR5.
Our results thus far demonstrated that B-oligomer–
treated cells did not signal after MIP-1b stimulation. We
wished to demonstrate that signaling initiated by HIV-1
binding was also affected. Because our attempts to detect
Ca21 flux (14) or Pyk2 phosphorylation (13) in primary
cells after inoculation with HIV-1 or gp120 were unsuc-
cessful, we decided to use receptor capping as an indicator
of HIV-1–induced signaling. Inoculation of PBMC cul-
tures with either R5 (Fig. 6 A) or X4 (Fig. 6 B) HIV-1
strains, or their corresponding gp120s (Table I), induced
a characteristic cocapping of chemokine receptors with
CD4. The fact that we were able to detect capped CCR5
and CXCR4 using antibodies that compete with gp120 for
chemokine receptor binding suggests that the observed sig-
nal came from free receptors that cocapped together with
gp120-occupied receptors. Such interpretation is consis-
tent with previously observed gp120-induced association
of CD4 with several surface molecules, such as CD3,
CD45RA, CD26, and HLA class I (41, 42), with
RANTES-induced colocalization of CXCR4 and CD4
(43), and with cocapping of CCR2 and CCR5 in response
to MCP-1 or RANTES (44).
Pretreatment of the cells with B-oligomer for 10 min
prevented capping of HIV-1 receptors, but only when cap-
ping was induced by R5 HIV-1 (Fig. 6 A). This result indi-
cates that capping is mediated by HIV-1–induced signaling
from chemokine receptors, rather than from CD4, and that
treatment with B-oligomer blocks this signal. To further il-
lustrate the role of signaling from chemokine receptors in
capping, we analyzed the effect of B-oligomer on capping
induced by SDF-1a and MIP-1b. This analysis was con-
founded by rapid downregulation of CXCR4 or CCR5
after stimulation with SDF-1a or MIP-1b, respectively.
Nevertheless, results presented in Table I demonstrate that
B-oligomer blocked capping induced by MIP-1b, but not
by SDF-1a. Similar to HIV-1– or gp120-induced polariza-
tion, the capping involved not only the ligand-specific re-
ceptor, but also other molecules, including CD4. This
result suggests that signaling from chemokine receptors in-
duces a major actin-dependent rearrangement of cellular
membrane.
Taken together, the results presented in this report sug-
gest that the inhibitory effect of PTX and its B-oligomer
on HIV-1 infection of primary cells is mediated through
desensitization of CCR5. Exposure to B-oligomer causes T
cells to lose signaling activity associated with binding of the
natural CCR5 ligand, MIP-1b, and to fail to cap after
binding of R5 HIV-1; however, ligand-binding activity is
Table I. Quantification of Receptor Capping
CCR5* CXCR4‡
CD4/CCR5§ CD4/CXCR4i CD4/CXCR4¶
cont. B-ol. cont. B-ol. cont. B-ol.
MIP-1b 6 1 1 5 –––– 4 09
HIV-192US660 – – 5 3 1 0 ––––
gp120JR-FL – – 66 – 14 – 39 3
SDF-1a 34 27 34 33 12 9 17 15
HIV-1LAI – – – – 30 26 – –
gp120LAI – – 50 – 15 – 15 20
Cells were treated with the B-oligomer of PTX (1 nM) for 10 min (B-ol.) or left untreated (cont.), and then incubated with the indicated stimulant
for 60 min. Capping was assayed by immunofluorescent microscopy (see Fig. 6). Approximately 200 cells were counted for each treatment. For
some treatments, experiment was repeated two to three times with similar results.
*Percentage of CCR51 cells exhibiting capping. Approximately 30% of all cells were CCR51.
‡Percentage of CXCR41 cells exhibiting capping. Approximately 95% of all cells were CXCR41.
§Percentage of CD41/CCR51 cells exhibiting capping. Approximately 10% of all cells were CD41/CCR51.
iPercentage of CD41/CXCR41 cells exhibiting capping. Approximately 35% of all cells were CD41/CXCR41.
¶Percentage of CCR51/CXCR41 cells exhibiting capping. Approximately 30% of all cells were CCR51/CXCR41. 604 HIV-1 Inhibition by the Binding Subunit of Pertussis Toxin
preserved. The role of receptor capping in HIV-1 infection
of primary cells, and the nature of signals involved in the
regulation of capping are now under investigation in our
laboratory. It is clear that receptor capping is not required
for binding of the virus, but it might be necessary for fusion
with primary cells. In addition to the potential value of the
B-oligomer as an anti-HIV agent, these studies may define
new targets in the search for novel therapeutic approaches
against HIV infection.
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